Literature DB >> 20693850

Artificial antigen-presenting cells for use in adoptive immunotherapy.

Cameron J Turtle1, Stanley R Riddell.   

Abstract

The observation that T cells can recognize and specifically eliminate cancer cells has spurred interest in the development of efficient methods to generate large numbers of T cells with specificity for tumor antigens that can be harnessed for use in cancer therapy. Recent studies have demonstrated that during encounter with tumor antigen, the signals delivered to T cells by professional antigen-presenting cells can affect T-cell programming and their subsequent therapeutic efficacy. This has stimulated efforts to develop artificial antigen-presenting cells that allow optimal control over the signals provided to T cells. In this review, we will discuss the advantages and disadvantages of cellular and acellular artificial antigen-presenting cell systems and their use in T-cell adoptive immunotherapy for cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20693850      PMCID: PMC2929753          DOI: 10.1097/PPO.0b013e3181eb33a6

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  78 in total

1.  Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres.

Authors:  Steffen Walter; Leah Herrgen; Oliver Schoor; Gundram Jung; Dorothee Wernet; Hans-Jörg Bühring; Hans-Georg Rammensee; Stefan Stevanović
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 3.  Use of tumour-responsive T cells as cancer treatment.

Authors:  Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

4.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Authors:  L Zitvogel; A Regnault; A Lozier; J Wolfers; C Flament; D Tenza; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

5.  Cancer vaccines: a road map for the next decade.

Authors: 
Journal:  Curr Opin Immunol       Date:  1996-10-01       Impact factor: 7.486

6.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.

Authors:  J B Latouche; M Sadelain
Journal:  Nat Biotechnol       Date:  2000-04       Impact factor: 54.908

7.  Binding of cytotoxic T-lymphocytes to supported lipid monolayers containing trypsinized H-2Kk.

Authors:  M Nakanishi; A A Brian; H M McConnell
Journal:  Mol Immunol       Date:  1983-11       Impact factor: 4.407

8.  Secondary cytolytic T lymphocyte stimulation by purified H-2Kk in liposomes.

Authors:  S H Herrmann; M F Mescher
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

9.  Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction.

Authors:  Karin Schilbach; Gunter Kerst; Steffen Walter; Matthias Eyrich; Dorothee Wernet; Rupert Handgretinger; Weidong Xie; Hans-Georg Rammensee; Ingo Müller; Hans-Jörg Bühring; Dietrich Niethammer
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

10.  Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.

Authors:  Raffaella Fontana; Marco Bregni; Arcadi Cipponi; Laura Raccosta; Cristina Rainelli; Daniela Maggioni; Francesca Lunghi; Fabio Ciceri; Sylvain Mukenge; Claudio Doglioni; Didier Colau; Pierre G Coulie; Claudio Bordignon; Catia Traversari; Vincenzo Russo
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

View more
  37 in total

Review 1.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Enterotoxins can support CAR T cells against solid tumors.

Authors:  Bianca von Scheidt; Minyu Wang; Amanda J Oliver; Jack D Chan; Metta K Jana; Aesha I Ali; Fiona Clow; John D Fraser; Kylie M Quinn; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-25       Impact factor: 11.205

Review 3.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

4.  RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses.

Authors:  Qian Ding; Jian Chen; Xiaohui Wei; Wenqiang Sun; Junhua Mai; Yanzhu Yang; Yuhong Xu
Journal:  Pharm Res       Date:  2012-08-10       Impact factor: 4.200

Review 5.  Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.

Authors:  Wenji Sun; Priyanka B Subrahmanyam; James E East; Tonya J Webb
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

6.  Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

Authors:  Partow Kebriaei; Helen Huls; Bipulendu Jena; Mark Munsell; Rineka Jackson; Dean A Lee; Perry B Hackett; Gabriela Rondon; Elizabeth Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2012-01-17       Impact factor: 5.695

Review 7.  Nanoengineering approaches to the design of artificial antigen-presenting cells.

Authors:  Joel C Sunshine; Jordan J Green
Journal:  Nanomedicine (Lond)       Date:  2013-07       Impact factor: 5.307

8.  Biomimetic Nanoparticle Vaccines for Cancer Therapy.

Authors:  Ashley V Kroll; Yao Jiang; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Biosyst       Date:  2018-11-13

Review 9.  T cell immunotherapy enhanced by designer biomaterials.

Authors:  Zachary S Dunn; John Mac; Pin Wang
Journal:  Biomaterials       Date:  2019-06-14       Impact factor: 12.479

Review 10.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.